duchenn
muscular
dystrophi
sever
muscl
wast
xlink
genet
diseas
affect
children
character
loss
muscl
function
lead
decreas
ambul
patient
succumb
cardiac
respiratori
failur
diseas
caus
almost
complet
absenc
dystrophin
protein
due
outoffram
mutat
dmd
gene
dystrophin
import
protein
cytoskelet
structur
normal
muscl
function
play
vital
role
membran
stabil
signal
patient
dmd
suffer
sever
cardiomyopathi
although
degre
cardiac
involv
vari
patient
cardiomyopathi
gener
manifest
year
age
preval
patient
year
age
patient
first
exhibit
left
ventricl
lv
dilat
hypertrophi
progress
stage
known
dilat
cardiomyopathi
dcm
addit
cardiomyopath
featur
includ
decreas
fraction
shorten
electrocardiogram
ecg
abnorm
approxim
patient
also
display
tachycardia
exhibit
increas
patholog
heart
rate
variabl
ecg
abnorm
associ
morpholog
chang
cardiac
muscl
thin
thick
filament
heart
myocardi
fibrosi
conduct
defect
inde
deep
q
wave
abnorm
associ
later
wall
scar
cardiac
phenotyp
continu
deterior
dystroph
heart
undergo
hypertrophi
effort
cope
increas
wall
stress
impos
pressurevolum
overload
heart
undergo
maladapt
remodel
develop
dcm
approxim
patient
age
present
dcm
escal
year
age
preval
patient
adulthood
unfortun
sever
scoliosi
hamper
abil
accur
measur
cardiac
function
result
late
diagnosi
late
employ
treatment
mark
declin
cardiac
function
correl
increas
fibrot
deposit
imped
normal
heart
contract
fibrot
involv
preval
young
age
patient
year
escal
age
year
older
year
age
wide
use
mous
model
dmd
mdx
mous
point
mutat
exon
thu
prevent
product
dystrophin
protein
model
exhibit
obviou
skelet
phenotyp
includ
elev
creatin
kinas
ck
plasma
level
irregular
muscl
histolog
muscl
necrosi
declin
specif
forc
power
age
addit
respiratori
function
deterior
correl
degener
diaphragm
diseas
progress
age
mdx
mice
also
display
cardiac
phenotyp
increas
right
ventricl
rv
systol
volum
subsequ
reduct
rv
eject
fraction
ef
seen
month
increas
myocardi
fibrosi
appar
month
age
whilst
lv
cardiac
output
co
deterior
month
age
stroke
volum
sv
reduc
follow
reduct
lv
ef
month
although
model
critic
late
onset
cardiac
phenotyp
note
month
age
mdx
mice
exhibit
earli
intoler
dobutamin
stress
dmd
patient
ecg
record
consciou
mdx
mice
reveal
tachycardia
decreas
heart
rate
variabl
deep
q
wave
diminish
r
ratio
polyphas
rwave
shorter
qt
pr
interv
compar
control
major
dispar
mdx
mice
dmd
patient
rv
involv
occur
dmd
patient
cardiac
complic
contribut
significantli
earli
mortal
patient
interestingli
bmd
patient
also
exhibit
rv
chang
prior
lv
analog
mdx
cardiac
progress
dmd
patient
gener
receiv
earli
ventilatori
intervent
due
rapid
deterior
respiratori
function
intervent
would
like
improv
pulmonari
hypertens
thu
may
compens
rv
dysfunct
thu
evid
heart
import
system
affect
dmd
recent
research
focus
character
heart
patholog
therefor
review
focus
cardiac
aspect
dmd
first
result
absenc
dystrophin
molecular
heart
patholog
discuss
particularli
concentr
role
intracellular
calcium
increas
perturb
nitric
oxid
signal
neuron
synthas
nno
function
role
mitochondria
within
dmd
note
mani
cellular
pathway
import
dmd
patholog
eg
inflamm
matrix
metalloproteinas
function
autophagi
apoptosi
discuss
see
eg
shin
et
al
mosquiera
et
al
addit
current
therapi
involv
corticosteroid
respiratori
support
aceinhibitor
betablock
cardiac
resynchron
techniqu
review
lastli
preclin
therapeut
approach
present
investig
exon
skip
viral
gene
therapi
explor
within
context
improv
heart
patholog
membran
tear
suggest
aris
fragil
membran
due
absenc
dystrophin
would
make
membran
leaki
allow
influx
efflux
ion
protein
see
figur
within
heart
membran
sealant
lower
abolish
increas
influx
improv
left
ventricular
end
diastol
volum
mdx
mice
recent
contribut
membran
tear
increas
influx
debat
extens
review
allen
whitehead
indic
time
requir
increas
min
contract
correl
membran
tear
leakag
ion
protein
membran
also
explain
sac
lipid
peroxid
given
oppos
result
research
need
elucid
find
recent
sac
investig
possibl
reason
initi
influx
channel
open
upon
stretch
muscl
contract
allow
influx
cation
ion
inhibit
sac
follow
exposur
mechan
stress
significantli
diminish
rise
ventricular
cardiomyocyt
restor
protein
kinas
c
pkc
phospholipas
c
plc
signal
note
nonspecif
blocker
use
mean
may
also
block
na
channel
therefor
increas
could
mediat
direct
entri
ion
sac
indirect
entri
ncx
voltageg
channel
vgcc
open
due
nainduc
membran
depolar
see
figur
sac
compos
multipl
channel
subunit
implic
composit
sac
dmd
patholog
channel
includ
mechanosensit
transient
receptor
potenti
cation
trpc
channel
name
channel
activ
rosdepend
src
kinas
lead
influx
absenc
dystrophinassoci
nno
well
increas
induc
increas
ro
level
role
heart
remain
elus
express
level
channel
increas
age
mdx
mous
interestingli
recent
experi
see
involv
channel
skelet
myotub
whether
also
case
cardiomyocyt
unclear
channel
also
implic
dmd
upon
activ
migrat
plasma
membran
cultur
mdx
cardiomyocyt
exhibit
increas
express
plasma
membran
inhibit
channel
nonspecif
blocker
target
sirna
reduc
cellular
influx
upon
osmot
stress
channel
also
sensit
stretch
contract
inhibit
channel
mdx
heart
reduc
contract
arrhythmia
final
relev
heart
remain
establish
knockout
ko
mice
exhibit
dystroph
phenotyp
stretchinduc
contract
cardiomyocyt
induc
respons
voltagedepend
ltype
channel
implic
patholog
dmd
channel
link
factin
subsarcolemm
protein
includ
dystrophin
thought
involv
contract
mdx
mous
heart
ltype
channel
exhibit
delay
inactiv
rate
interestingli
even
though
action
potenti
durat
affect
signific
ecg
abnorm
observ
addit
viola
et
al
show
commun
ltype
channel
mitochondria
import
metabol
function
healthi
cell
commun
alter
mdx
cardiomyocyt
though
exact
protein
involv
unclear
intracellular
channel
sarcoplasm
reticulum
sr
involv
regul
serca
ryr
channel
see
figur
major
store
serca
pump
back
sr
increas
interestingli
express
level
serca
mdx
heart
appear
similar
wildtyp
wt
though
report
shown
downregul
may
attribut
age
older
mice
would
exhibit
reduct
serca
channel
ryr
activ
bind
therebi
lead
releas
stimul
excitationcontract
ec
coupl
hyperphosphoryl
channel
possibl
protein
kinas
pka
camkii
could
make
sensit
persist
hyperphosphoryl
ryr
lead
dissoci
calstabin
stabil
protein
turn
disrupt
regul
wherebi
sr
becom
leaki
ultim
result
heart
failur
indirect
evid
ryr
involv
mdx
heart
seen
wherebi
increas
sr
leak
observ
month
old
mice
worsen
patholog
older
mice
event
also
observ
arrhythmia
heart
failur
lastli
receptor
activ
downstream
product
plc
applic
plc
inhibitor
reduc
concentr
heart
mdx
mice
compar
wt
older
mdx
anim
month
show
larger
diastol
decreas
upon
inhibit
compar
wt
result
indic
involv
plc
downstream
effect
diastol
concentr
heart
moreov
also
indic
age
play
import
role
increas
intracellular
concentr
much
work
done
elucid
role
dmd
patholog
suggest
interact
multipl
mechan
possibl
uncov
avenu
play
import
role
addit
mechan
propos
far
import
second
messeng
cell
physiolog
signal
molecul
nitric
oxid
product
regul
synthas
no
three
isoform
neuron
no
nno
endotheli
no
eno
induc
no
ino
nno
eno
constitut
express
muscl
heart
activ
calmodulin
eno
associ
caveolin
sarcolemma
nno
associ
dgc
close
proxim
serca
ryr
convers
ino
express
cell
inflamm
partli
respons
inflammatori
respons
seen
dmd
local
no
enzym
within
cell
crucial
function
activ
sever
second
thu
need
reach
target
quickli
howev
dmd
nno
displac
consider
lower
nno
activ
level
patient
mdx
mice
function
nno
heart
current
still
investig
sever
knockout
studi
implic
role
lv
systol
function
shorten
myocyt
remain
elus
due
oppos
result
overproduct
nno
associ
cardiac
depress
increas
chanc
heart
failur
absenc
nno
impact
sever
downstream
pathway
includ
mitochondri
respiratori
chain
ryr
regul
reactiv
oxygen
speci
ro
control
induc
cell
damag
increas
transgen
upregul
nno
mdx
mous
restor
heart
phenotyp
decreas
inflammatori
marker
fibrosi
apoptosi
aspect
heart
function
also
improv
stroke
volum
eject
fraction
togeth
studi
underscor
import
nno
function
interact
heart
loss
molecul
result
worsen
heart
function
though
research
need
elucid
exact
function
cell
mitochondria
import
part
energi
metabol
healthi
muscl
contract
addit
role
also
function
store
suppli
take
cell
furthermor
involv
ro
product
play
import
role
cell
death
necrosi
apoptosi
mdx
mice
display
disturb
mitochondri
function
thu
organel
thought
play
role
dmd
alter
mitochondri
energi
product
one
first
pathophysiolog
chang
known
occur
mdx
heart
mdx
mice
assess
week
age
consid
precardiomyopath
stage
reveal
slight
shift
energi
consumpt
normal
util
fatti
acid
higher
usag
carbohydr
function
oxid
capac
mitochondria
also
disturb
mdx
mous
model
suggest
mild
oxid
stress
induc
reduct
oxid
phosphoryl
therebi
reduc
product
atp
due
energi
demand
cell
inabl
mitochondria
suppli
cell
cardiomyocyt
sever
affect
mitochondria
also
target
signal
downstream
effector
overexpress
guanylyl
cyclas
gc
activ
cgmp
week
old
mdx
mice
improv
muscl
function
cardiac
endur
led
reduc
heart
product
lactat
dehydrogenas
marker
tissu
damag
gc
transgen
mdx
mous
heart
still
display
slight
shift
energi
metabol
fatti
acid
carbohydr
substrat
mitochondri
function
enhanc
higher
level
compound
citric
acid
cycl
observ
given
data
lack
dystrophin
seem
disrupt
metabol
heart
howev
remain
unclear
bring
chang
metabol
whether
compensatori
detriment
mechan
addit
perturb
energi
metabol
exhibit
mitochondria
dystrophindefici
cell
increas
intracellular
level
detriment
effect
mitochondria
rise
thought
induc
sudden
increas
mitochondri
membran
permeabl
mitochondri
permeabl
transit
pore
ptp
ptp
voltagesensit
channel
increas
mitochondri
concentr
induc
open
channel
lead
swell
shortterm
open
channel
thought
benefici
mitochondria
abl
regul
intracellular
ro
balanc
howev
longterm
open
channel
thought
detriment
cell
induc
necrosi
mitochondria
ruptur
mitochondria
contribut
myofib
necrosi
current
cure
dmd
therefor
therapi
limit
manag
symptom
three
predomin
treatment
approach
includ
corticosteroid
order
amelior
skelet
muscl
phenotyp
mechan
respiratori
support
cardiac
assess
treatment
corticosteroid
shown
markedli
improv
muscl
strength
function
recent
studi
implic
corticosteroid
stabil
pulmonari
function
prolong
ambul
reduc
preval
scoliosi
addit
associ
delay
onset
cardiomyopathi
year
corticosteroid
treatment
howev
unfortun
side
effect
includ
cush
syndrom
short
statur
hypertens
hyperglycemia
cataract
osteoporosi
hamper
use
corticosteroid
deterior
respiratori
muscl
result
respiratori
insuffici
pulmonari
hypertens
increas
pulmonari
hypertens
compound
cardiac
function
lead
dcm
thu
mechan
support
requir
soon
nocturn
hypoventil
appar
order
maintain
adequ
ventil
cough
reflex
noninvas
positivepressur
ventil
nippv
machin
mechan
insufflationexsuffl
devic
prefer
respiratori
support
devic
substanti
reduc
mortal
dmd
patient
lastli
approach
design
specif
target
cardiac
involv
includ
angiotensinconvert
enzym
ace
inhibitor
betablock
diuret
ace
inhibitor
gener
implement
lv
systol
function
declin
inhibitor
prevent
convers
angiotensini
angiotensinii
angii
therebi
reduc
circul
level
angii
addit
ace
inhibitor
reduc
kinaseii
increas
bradykinin
level
shown
reduc
peripher
vascular
resist
improv
endotheli
function
prevent
fibrosi
use
ace
inhibitor
treatment
dmd
patient
eject
fraction
ef
show
signific
improv
cardiac
function
rel
pretherapi
result
p
delay
progress
cardiomyopathi
betablock
prevent
bind
catecholamin
interf
bind
thu
reduc
sympathet
nervou
system
activ
therefor
prescrib
arrhythm
patient
symptomat
stabl
systol
dysfunct
clinician
often
prescrib
cocktail
ace
inhibitor
diuret
significantli
improv
cardiac
function
surviv
dmd
patient
howev
regular
cardiac
assess
imper
ensur
correct
treatment
regimen
observ
administr
metoprolol
detriment
rv
function
administ
earli
stage
cardiomyopath
progress
dmd
patient
unrespons
pharmacolog
treatment
cardiac
resynchron
therapi
may
consid
ie
patient
low
lv
ef
accompani
ventricular
dyssynchroni
qr
ms
patient
biventricular
pacemak
surgic
instal
allow
pace
septal
later
wall
lv
measur
left
ventricular
assist
devic
heartmat
ii
heartwar
also
employ
effort
reduc
heart
failur
case
devic
markedli
improv
cardiac
function
qualiti
life
thu
demonstr
potenti
dmd
patient
respond
convent
intervent
measur
sever
drug
alreadi
commerci
avail
may
benefit
dmd
patient
therefor
investig
anim
model
dmd
explor
therapeut
potenti
synthet
copolym
poloxam
stabil
sarcolemma
shown
improv
cardiac
phenotyp
even
prevent
isoproterenoldobutamineinduc
cardiomyopathydeath
phosphodiesteras
inhibitor
sildenafil
act
cgmp
pathway
enhanc
nocgmp
signal
signal
impair
mdx
mice
administr
sildenafil
improv
contractil
perform
cardiac
metabol
sarcolemm
integr
furthermor
revers
patholog
cardiac
dysfunct
mdx
heart
improv
diaphragmat
muscl
strength
therebi
enhanc
respiratori
function
unfortun
translat
clinic
cardiac
function
improv
observ
patient
clinic
trial
termin
earli
import
note
howev
rel
small
cohort
patient
use
studi
higher
number
may
better
elucid
underli
mechan
addit
drug
losartan
pirfenidon
investig
antifibrot
properti
drug
inhibit
express
therebi
reduc
fibrosi
seen
improv
cardiac
patholog
function
pharmacolog
measur
target
signal
pathway
also
util
shown
slower
muscular
dystrophi
progress
inde
histon
deacteylas
activ
hdac
perturb
dmd
may
inhibit
use
donor
also
shown
benefit
heart
patholog
addit
combin
nonsteroid
antiinflammatori
drug
ibuprofen
donor
isosorbid
dinitr
capabl
prevent
morpholog
chang
heart
mdx
mice
recent
phase
clinic
trial
use
combinatori
therapi
demonstr
excel
safeti
profil
healthi
patient
provid
solid
basi
trial
muscular
dystrophi
patient
drug
demonstr
encourag
result
anim
model
dmd
hope
infer
clinic
benefit
patient
furthermor
drug
may
present
viabl
combinatori
therapi
may
administ
conjunct
treatment
specif
aim
correctingcompens
dystrophin
mutat
utrophin
upregul
one
first
therapeut
strategi
develop
compens
lack
dystrophin
cell
adult
cell
utrophin
mainli
found
regener
cell
neuromuscular
myotendin
junction
thought
utrophin
could
import
determin
actin
filament
length
develop
utrophin
homologu
dystrophin
molecular
weight
kda
similar
amino
acid
composit
although
rod
domain
significantli
shorter
despit
function
differ
utrophin
appear
mani
bind
protein
includ
certain
compon
dapc
factin
given
characterist
believ
utrophin
could
partial
compens
dystrophin
function
consid
viabl
option
therapeut
purpos
consequ
upregul
utrophin
amelior
dmd
patholog
improv
function
deficit
investig
evid
support
concept
come
dystrophinutrophin
doubl
knockout
mous
model
anim
exhibit
worsen
skelet
muscl
cardiac
patholog
life
span
month
indic
utrophin
compens
absenc
dystrophin
anim
posit
effect
utrophin
upregul
also
seen
mdx
skelet
muscl
though
note
heart
correct
anoth
strategi
call
biglycan
local
utrophin
sarcolemma
though
new
utrophin
gener
tivorsan
pharmaceut
wwwtrivorsancom
promis
utrophin
target
drug
smt
drug
discov
small
molecul
screen
current
undergo
clinic
trial
applic
drug
mdx
mice
increas
utrophin
rna
protein
level
mice
exhibit
reduc
patholog
improv
muscl
function
heart
also
display
presenc
utrophin
function
test
perform
phase
ia
ib
clinic
trial
perform
phase
ia
trial
show
mild
sideeffect
occur
higher
dose
phase
ib
trial
complet
result
yet
publish
clinicaltrialsgov
identifi
see
tabl
note
utrophin
compens
unabl
complet
restor
patholog
instanc
utrophin
unabl
bind
nno
key
factor
dmd
pathophysiolog
therefor
given
structur
differ
compar
dystrophin
yet
clear
utrophin
fulli
compens
absenc
dystrophin
nevertheless
utrophin
upregul
remain
valuabl
therapeut
option
could
benefit
patient
irrespect
underli
mutat
caus
diseas
small
number
patient
nonsens
mutat
lead
prematur
stopcodon
therebi
disrupt
open
read
frame
antibacteri
drug
call
aminoglycosid
abl
readthrough
prematur
stop
codon
without
affect
normal
stop
codon
therebi
restor
read
frame
gener
function
dystrophin
protein
gentamicin
negamycin
examin
mdx
mice
wherebi
low
level
dystrophin
express
observ
gentamycin
test
dmd
patient
earlier
clinic
trial
saw
contradictori
inconclus
result
later
trial
saw
low
level
dystrophin
express
patient
subsequ
highthroughput
screen
identifi
smallmolecul
abl
induc
readthrough
prematur
stop
codon
shown
signific
promis
vitro
vivo
studi
major
concern
drug
possibl
offtarget
effect
though
indic
yet
nonetheless
posit
preclin
result
led
ataluren
undergo
clinic
trial
wherebi
drug
well
toler
importantli
readthrough
normal
stop
codon
occur
trial
show
signific
function
outcom
though
interestingli
sever
subgroup
posit
affect
treatment
mention
heart
clinicaltrialsgov
identifi
see
tabl
result
clinic
trial
clearli
show
better
understand
regard
subgroup
patient
function
outcom
need
studi
aim
identifi
effect
drug
induc
readthrough
sensit
smallmolecul
screen
perform
identifi
compound
compound
subsequ
administ
intramuscularli
intraven
mdx
mice
demonstr
better
efficaci
restor
dystrophin
skelet
muscl
especi
heart
gentamicin
addit
muscl
function
improv
serum
ck
level
decreas
mdx
mice
treat
provid
promis
new
therapeut
molecul
patient
prematur
stop
codon
anoth
therapeut
strategi
undergo
develop
use
viral
vector
deliv
dystrophin
transgen
cell
given
dystrophin
enorm
size
multipl
studi
endeavor
distinguish
integr
compon
dystrophin
gene
develop
shorten
truncat
version
may
insert
viral
capsid
mini
microdystrophin
sever
virus
consid
potenti
deliveri
vector
includ
lentiviru
adenoviru
adenoassoci
viru
aav
see
tabl
order
safe
appli
aav
viru
modifi
exclud
viral
gene
leav
essenti
repeat
replic
recombin
aav
raav
aav
vector
requir
cotransfect
vector
carri
compon
necessari
replic
differ
aav
serotyp
exhibit
differ
tropism
shown
particular
promis
mdx
heart
use
mini
microdystrophin
microdystrophin
success
transfect
induct
dystrophin
ta
diaphragm
heart
young
mdx
mice
interestingli
howev
heart
function
recov
even
though
dystrophin
restor
heart
heart
mass
normal
inject
old
mdx
mice
also
produc
posit
result
suggest
even
though
mdx
muscl
significantli
damag
diseas
treatment
still
capabl
improv
muscl
patholog
proven
particularli
effici
transfect
heart
minidystrophin
administ
intraven
golden
retriev
muscular
dystrophi
grmd
dog
reveal
vari
dystrophin
express
depend
muscl
analyz
also
present
heart
microdystrophin
administr
young
adult
mdx
mice
also
induc
dystrophin
express
improv
cardiac
function
despit
posit
result
immunolog
respons
aav
viru
still
observ
larger
anim
human
moreov
high
titer
viru
necessari
induc
effect
dystrophin
express
muscl
cell
effort
reduc
chimer
vector
vector
contain
codonoptim
microdystrophin
gener
intraven
inject
week
old
mdx
mice
lower
titer
level
viru
result
almost
transfect
effect
dystrophin
express
skelet
muscl
heart
improv
muscl
function
moreov
immunolog
respons
observ
overal
viral
vector
promis
candid
deliveri
dystrophin
gene
howev
special
care
taken
regard
immunogen
human
popul
carri
antibodi
toward
mani
preval
virus
aav
though
immunosuppress
may
implement
reduc
risk
moreov
incorrect
insert
viru
host
genom
may
occur
vector
lentivirus
lastli
repeat
administr
problemat
due
presenc
neutral
antibodi
first
administr
research
need
elimin
concern
cellbas
therapi
healthi
dystrophinexpress
cell
transplant
dmd
patient
tissu
integr
healthi
adult
muscl
cell
ideal
also
copopul
satellit
cell
cell
deriv
either
healthi
precursor
cell
patient
cell
genet
modifi
vitro
sever
differ
muscl
precursor
cell
explor
therapeut
purpos
dmd
name
myoblast
fibroblast
bonemarrow
deriv
stem
cell
stem
cell
mesangioblast
see
tabl
recent
shift
use
induc
pluripot
stem
ip
cell
observ
inde
human
ip
cell
differenti
muscl
precursor
cell
inject
ta
muscl
immunocompromis
mdx
mous
model
follow
inject
dystrophin
protein
restor
regener
led
higher
dystrophin
level
function
test
show
improv
experi
illustr
ip
cell
abl
integr
muscl
cell
settl
satellit
cell
popul
sever
group
aim
util
genet
modifi
patient
precursor
cell
treatment
would
circumv
immunolog
suppress
need
introduc
foreign
materi
bodi
genom
cell
modifi
vitro
use
nucleas
wherebi
recent
talen
use
splice
correct
dystrophin
gene
util
ip
cell
vitro
induc
exon
skip
shift
read
frame
insert
miss
exon
success
result
subsequ
ip
cell
differenti
skelet
muscl
cell
dystrophin
express
observ
knockin
miss
exon
effect
given
novelti
work
studi
focus
skelet
cell
encompass
cardiomyocyt
result
offer
interest
prospect
dystrophin
heart
restor
overal
util
genet
modifi
cell
patient
would
valuabl
treatment
consid
immunolog
respons
howev
abil
induc
sustain
adequ
dystrophin
level
remain
difficult
current
deliveri
progenitor
cell
success
done
intramuscularli
yet
would
allow
treatment
one
muscl
time
muscl
like
diaphragm
heart
would
restor
addit
high
titer
modifi
cell
need
significantli
alter
phenotyp
function
sever
obstacl
yet
overcom
techniqu
appear
promis
may
prove
effect
antisens
oligonucleotid
aon
anoth
viabl
approach
treat
dmd
patient
specif
util
skip
exon
mutat
delet
dystrophin
gene
order
correct
aberr
read
frame
aon
short
singl
strand
dna
sequenc
complementari
target
premrna
splice
site
therebi
steric
block
splice
enhanc
skip
desir
exon
produc
function
albeit
shorter
dystrophin
protein
therapi
capabl
treat
dmd
patient
dystrophin
mutat
specif
patient
delet
small
mutat
duplic
signific
shortfal
therapi
aon
specif
target
one
exon
time
therefor
current
effort
focus
exon
would
assist
greatest
number
patient
predomin
aon
chemistri
current
undergo
clinic
evalu
phosphorodiamid
morpholino
oligom
pmo
methyl
phosphorothio
shown
promis
result
clinic
see
tabl
although
chemistri
demonstr
potenti
treat
dmd
confound
issu
rel
poor
system
deliveri
inabl
restor
dystrophin
heart
recent
new
aon
chemistri
tricyclodna
demonstr
mark
preclin
success
capabl
restor
dystrophin
skelet
muscl
heart
low
level
brain
dmd
mous
model
howev
note
posit
find
requir
multipl
dose
administr
high
dose
mgkg
per
week
effort
improv
deliveri
capac
aon
reduc
dose
requir
short
peptid
sequenc
cell
penetr
peptid
cpp
chemic
conjug
neutral
aon
pmo
facilit
deliveri
across
plasma
membran
multitud
studi
investig
peptid
conjug
aon
context
dmd
broadli
classifi
distinct
group
name
arginin
rich
pip
pnapmo
intern
peptid
phage
chimer
peptid
importantli
arginin
rich
pip
peptid
demonstr
cardiac
dystrophin
express
arginin
rich
cpp
conjug
pmo
first
show
activ
heart
inde
show
sustain
treatment
improv
cardiac
function
resist
dobutamin
stress
recent
seri
demonstr
dystrophin
express
heart
low
dose
mgkg
prevent
exerciseinduc
cardiomyopathi
follow
longterm
treatment
phage
peptid
less
success
restor
cardiac
dystrophin
function
except
phage
conjug
result
exon
skip
multipl
tissu
includ
heart
anoth
method
improv
deliveri
charg
aon
encapsul
liposom
nanoparticl
recent
advanc
given
rise
nanoparticl
bound
aon
demonstr
widespread
distribut
skelet
muscl
heart
thu
highlight
potenti
deliveri
method
new
innov
technolog
investig
includ
bispecif
splice
oligonucleotid
target
dystrophin
myostatin
regul
knockingin
delet
exon
use
meganucleas
given
current
develop
aon
therapi
dmd
field
surpris
varieti
novel
approach
develop
treatment
dmd
summar
except
tricyclodna
nake
aon
demonstr
limit
system
deliveri
inabl
restor
dystrophin
heart
wherea
conjug
cpp
use
encapsul
technolog
significantli
improv
upon
cpp
perspect
polyarginin
pip
cpp
display
widespread
dystrophin
restor
multipl
skelet
muscl
tissu
heart
nanoparticl
anoth
promis
deliveri
strategi
particularli
charg
aon
field
rapidli
evolv
hope
one
technolog
advanc
clinic
trial
near
futur
whilst
experiment
therapi
inspir
new
hope
patient
famili
affect
dmd
feasibl
clinic
translat
therapi
brought
question
speci
differ
consid
term
cellular
process
pathway
also
concern
immunolog
respons
mous
model
dmd
somewhat
resili
studi
dog
model
highlight
inevit
obstacl
particularli
due
complex
immun
system
imposs
avoid
given
requir
system
approach
treat
diseas
devast
entir
bodi
prevent
immunolog
respons
particularli
relev
cellbas
therapi
viral
vector
also
peptideconjug
aon
may
caus
complic
certainli
long
term
administr
nake
pmo
elicit
immunolog
respons
therapi
aminoglycosid
may
induc
offtarget
toxicolog
affect
ultim
order
substanti
amelior
abrog
diseas
target
underli
defect
specif
lack
dystrophin
protein
requir
current
pharmacolog
intervent
delay
partial
amelior
symptom
diseas
therefor
imper
one
inde
new
therapi
altogeth
abl
overcom
obstacl
bypass
innat
immun
system
current
understand
duchenn
muscular
dystrophi
increas
significantli
last
decad
absenc
dystrophin
protein
give
rise
complex
patholog
involv
mani
differ
process
cell
play
intric
part
diseas
progress
much
research
alreadi
perform
indic
import
mitochondria
second
messeng
organel
cell
howev
given
gap
still
remain
knowledg
seem
like
unknown
protein
pathway
also
affect
diseas
patholog
furthermor
dystrophin
express
bodywid
import
individu
system
heart
consid
specif
mechanist
find
skelet
muscl
patholog
may
necessarili
appli
heart
moreov
comparison
molecular
aspect
dystrophin
function
differ
cell
type
could
provid
valuabl
inform
knowledg
gain
improv
understand
molecular
patholog
pathway
provid
way
develop
assess
effect
treatment
avail
steroid
drug
improv
made
amelior
skelet
muscl
phenotyp
whilst
pharmacolog
treatment
stabil
cardiac
function
ace
inhibitor
betablock
use
mortal
cardiorespiratori
complic
dmd
patient
remain
high
moreov
whilst
experiment
therapi
develop
may
benefit
cardiac
aspect
diseas
clinic
trial
date
focus
exclus
benefici
effect
drug
treatment
skelet
muscl
function
without
consid
impact
heart
function
therefor
increas
focu
heart
essenti
term
exist
treatment
effect
heart
function
also
critic
novel
treatment
could
develop
specif
restor
dystrophin
upregul
utrophin
cardiac
muscl
result
clinic
benefit
patient
